The endothelium-dependent effect of RTEF-1 in pressure overload cardiac hypertrophy: Role of VEGF-B

Cardiovascular Research

Volumn 90, Issue 2, 2011, Pages 325-334

  Xu, Ming ^a,b   Jin, Yi ^b   Song, Qinhui ^b   Wu, Jiaping ^b   Philbrick, Melissa J ^b   Cully, Brittany L ^b   An, Xiaojin ^b   Guo, Lin ^b   Gao, Feng ^a   Li, Jian ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiomyocyte; Endothelial cell; Endothelium; Growth factor; Hypertrophy; Hypoxia; Related transcription enhancer factor 1; Transcription factor; Vascular endothelial growth factor B

Indexed keywords

CELL PROTEIN; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RELATED TRANSCRIPTION ENHANCE FACTOR 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE ACTIVITY; GENE EXPRESSION; HEART HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE WALL; HEART MUSCLE; HEART MUSCLE CELL; HEART WEIGHT; MOLECULAR MECHANICS; MOUSE; MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ANOXIA; ANTIGENS, CD; BLOOD PRESSURE; CADHERINS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MUSCLE PROTEINS; MYOBLASTS; MYOCARDIUM; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 79955412822     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq400     Document Type: Article

References (32)

1. Hsieh PC, Davis ME, Lisowski LK, Lee RT. Endothelial-cardiomyocyte interactions in cardiac development and repair. Annu Rev Physiol 2006;68:51-66.
2. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 2001;98:5780-5785. (Pubitemid 32435719)
3. Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest 2007;117:3176-3179. (Pubitemid 350096973)
4. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hyper-trophy to failure in response to pressure overload. Hypertension 2006;47:887-893. (Pubitemid 44297560)
5. Karch R, Neumann F, Ullrich R, Neumuller J, Podesser BK, Neumann M et al. The spatial pattern ofcoronary capillaries in patients with dilated, ischemic, or inflamma-tory cardiomyopathy. Cardiovasc Pathol 2005;14:135-144. (Pubitemid 40725589)
6. 1-adrenergic signaling in hypertrophied cardiac myocytes. J Biol Chem 2000;275:17476-17480. (Pubitemid 30430787)
7. Shie JL, Wu G, Wu J, Liu FF, Laham RJ, Oettgen P et al. RTEF-1, a noveltranscriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. J Biol Chem 2004;279:25010-25016. Epub 22004 Apr 25018. (Pubitemid 38756749)
8. Farrance IK, Ordahl CP. The role oftranscription enhancer factor-1 (TEF-1) related proteins in the formation of M-CAT binding complexes in muscle and non-muscle tissues. J Biol Chem 1996;271:8266-8274. (Pubitemid 26108659)
9. Gan Q, Yoshida T, Li J, Owens GK. Smooth muscle cells and myofibroblasts use dis-tinct transcriptional mechanisms for smooth muscle α-actin expression. Circ Res 2007; 101:883-892. Epub 2007 Sep 2006. (Pubitemid 350287175)
10. Chen HH, Baty CJ, Maeda T, Brooks S, Baker LC, Ueyama T et al. Transcription enhancer factor-1-related factor-transgenic mice develop cardiac conduction defects associated with altered connexin phosphorylation. Circulation 2004;110: 2980-2987. Epub 2004 Nov 2981. (Pubitemid 39491987)
11. Appukuttan B, McFarland TJ, Davies MH, Atchaneeyasakul LO, Zhang Y, Babra B et al. Identification of novel alternatively spliced isoforms of RTEF-1 within human ocular vascular endothelial cells and murine retina. Invest Ophthalmol Vis Sci 2007;48: 3775-3782. (Pubitemid 351261117)
12. Nash AD, Baca M, Wright C, Scotney PD. The biology ofvascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther 2006;19:61-69. (Pubitemid 41606854)
13. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D et al. A gene atlas ofthe mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004; 101:6062-6067. (Pubitemid 38520528)
14. Mould AW, Greco SA, Cahill MM, Tonks ID, Bellomo D, Patterson C et al. Transgenic overexpression ofvascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ Res 2005;97:e60-e70.
15. Aase K, von Euler G, Li X, Ponten A, Thoren P, Cao R et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect Circulation 2001; 104:358-364. (Pubitemid 32666961)
16. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009;106:6152-6157.
17. Karpanen T, Bry M, Ollila HM, Seppanen-Laakso T, Liimatta E, Leskinen H et al. Over-expression ofvascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res 2008;103:1018-1026.
18. Zentilin L, Puligadda U, Lionetti V, Zacchigna S, Collesi C, Pattarini L et al. Cardiomyo-cyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and pre-serves cardiac function after myocardial infarction. FASEBJ 2010;24:1467-1478.
19. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ et al. Seg-regation of atrial-specific and inducible expression of an atrial natriuretic factor trans-gene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 1991; 88:8277-8281. (Pubitemid 21915339)
20. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 2008; 117:3099-3108. Epub 2008Jun 3092.
21. Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010;120:1506-1514.
22. Brutsaert DL Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003;83:59-115. (Pubitemid 36459878)
23. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is pro-grammed by the tissue microenvironmentJ Cell Biol 1997;138:1117-1124. (Pubitemid 27386460)
24. Wu G, Mannam AP, Wu J, Kirbis S, Shie JL, Chen C et al. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role ofVEGF. Am J Physiol Heart Circ Physiol 2003;285:H2420-H2429. (Pubitemid 37443058)
25. Mohacsi A, Magyar J, Tamas B, Nanasi PP. Effects of endothelins on cardiac and vascular cells: new therapeutic target for the future? Curr Vasc Pharmacol 2004;2: 53-63. (Pubitemid 38855015)
26. Kuruvilla L, Kartha CC Molecular mechanisms in endothelial regulation of cardiac function. Mol Cell Biochem 2003;253:113-123. (Pubitemid 37321717)
27. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y et al. p53-induced inhi-bition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446: 444-448. (Pubitemid 46474597)
28. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J et al. Comparison ofVEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997;14:2475-2483. (Pubitemid 27268166)
29. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-956.
30. Falk T, Zhang S, Sherman SJ. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkin-son's disease. Mol Neurodegener 2009;4:49.
31. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004;110:718-723. (Pubitemid 39056272)
32. 165, VEGF-R1, and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res 2000;87:644-647.